112. Lesokhin AM, Ansell SM, Armand P et al. Preliminary results of a phase I study of nivolumab Phosphoproteomics has been extensively used as a preclinical research tool to characterize the phosphorylated components of the cancer proteome. Advances in the field have yielded insights into new drug targets, mechanisms of disease progression and drug resistance, and biomarker discovery. However, application of this technology to clinical research has been challenging because of practical issues relating to specimen integrity and tumour heterogeneity. Beyond these limitations, phosphoproteomics has the potential to play a pivotal role in translational studies and contribute to advances in different tumour groups, including rare disease sites like sarcoma. In this review, we propose that deploying phosphoproteomic technologies in translational research may facilitate the identification of better defined predictive biomarkers for patient stratification, inform drug selection in umbrella trials and identify new combinations to overcome drug resistance. We provide an overview of current phosphoproteomic technologies, such as affinity-based assays and mass spectrometry-based approaches, and discuss their advantages and limitations. We use sarcoma as an example to illustrate the current challenges in evaluating targeted kinase therapies in clinical trials. We then highlight useful lessons from preclinical studies in sarcoma biology to demonstrate how phosphoproteomics may address some of these challenges. Finally, we conclude by offering a perspective and list the key measures required to translate and benchmark a largely preclinical technology into a useful tool for translational research.
introduction
Phosphoproteomics is the comprehensive analysis of the phosphorylated components of the cellular proteome. Over the last decade, advances in phosphoproteomic technologies and application workflows have led to its rapid adoption as a tool of choice for assessing cellular signalling networks. This has been fuelled in part by large-scale genomic analyses and functional screens which have uncovered multiple genetic aberrations in kinases and phosphatases, the key regulators of protein phosphorylation, in a range of different cancer types. In particular, phosphoproteomics has played an important role in defining the mechanistic links between oncogenic drivers and functional readouts. Prominent early examples include the identification of oncogenic BRAF signalling targets in melanoma [1] , the in-depth analysis of EGFR signalling in cancer cell lines [2] and the determination of ATM and ATR repair networks in response to DNA damage [3] . Despite its demonstrated utility in characterizing cancer signalling, phosphoproteomic applications in clinical and translational research are still lacking.
In this review, we propose that deploying phosphoproteomics in clinical trials and translational research has the potential to facilitate the discovery of better defined predictive biomarkers for patient stratification, inform drug selection in umbrella trials and identify new combinations to overcome drug resistance. We first provide a brief overview of the technical capabilities of phosphoproteomics, including current tools available and their advantages and limitations. We then use sarcoma as an example to illustrate the challenges facing the evaluation of targeted kinase therapies in oncology clinical trials. Useful lessons from sarcoma preclinical studies on how phosphoproteomics may address some of these challenges will be discussed. To conclude, we list the key measures required to translate and benchmark a largely preclinical technology into a useful tool for clinical trials and translational research.
current status of phosphoproteomic technologies
Phosphoproteomics offers the capability to accurately map the activation states of multiple proteins simultaneously and presents an attractive strategy for assessing kinase targets and signalling pathway responses to targeted kinase agents [1] [2] [3] [4] . These technologies provide significant advantages over standard laboratory techniques such as immunoblotting where the restricted dynamic range and sensitivity makes precise quantification challenging. Furthermore, immunoblotting lacks multiplexing capacity which limits the number of analytes which can be concurrently surveyed. Finally, this approach is inherently low throughput and in order to obtain large-scale signalling coverage and assess the phosphorylation states across multiple proteins within networks, significant labour and relatively large sample quantities are required.
Unlike other contemporary molecular profiling approaches like next-generation sequencing, there are currently no gold standard platforms for profiling kinase pathway activation by phosphoproteomics. As summarized in Table 1 , current technologies are broadly split into affinity-based assays and mass spectrometry (MS)-based approaches. The choice of which technologies to employ is largely driven by sample amounts, availability of phospho-specific antibodies, depth of signalling network coverage required and availability of specialist equipment and expertise.
Affinity-based strategies utilize specific antibodies to capture phosphorylated proteins from cell lysates, which are then detected by a secondary antibody recognizing the captured analyte labelled to generate a colorimetric or fluorescent signal [5] . Examples include antibody arrays and Luminex bead-based assays (Table 1) . Another affinity-base format is reverse phase protein arrays (RPPA) where multiple sample lysates are immobilized on a microarray format which is then incubated with a phospho-specific antibody before quantification [6] . Affinity-based assays have good multiplexing capability and are able to assess hundreds of phosphoproteins per experiment. They require very low amounts of sample, making them suitable for clinical studies where patient specimens may be limiting. These assays are amenable to highthroughput workflows and automation which allows for data collection from large sample cohorts. In addition, they do not rely on specialized equipment, facilitating ease of use and accessibility for most laboratories. The major disadvantage of this class of technologies is the heavy dependence on highly specific antibodies to each phosphoprotein of interest where antibody specificity is often difficult to assess.
MS facilitates the unbiased and quantitative analysis of thousands of phosphoproteins simultaneously in a single experiment. MS-based approaches range from focused studies that rely on capture reagents such as motif-specific antibodies to isolate phosphoproteins-bearing specific kinase motifs [7] to global approaches based on enrichment of cellular phosphoproteins using resins such as immobilized metal affinity chromatography or TiO 2 to characterize the global phosphorylation status in cancer cells [8] . MS-based assays can be further split into discovery or targeted experiments (Table 1) . In discovery MS, also known as shotgun or data-independent acquisition, enriched phosphopeptides are eluted into the mass spectrometer enabling identification of large numbers of phosphorylation sites in an unbiased fashion. Targeted MS relies on the generation of in silico peptide libraries which allow the instrument to scan and quantify specific phosphopeptides of interest [4, 9] . The major advantage of MS-based approaches is its ability to provide unparalleled depth in phosphoprotein coverage in an antibody-independent manner. However, compared with affinity-based assays, MS-based assays require much higher amounts of sample (up to milligram levels) and need considerable investment in infrastructure including high-resolution mass spectrometers and specialist expertise to accurately detect and quantify these signalling events. MS techniques are comparatively low throughput, although recent developments in automated workflows are likely to overcome this limitation [10] .
pazopanib as a case study: highlighting the challenges in clinical sarcoma research Sarcomas are tumours of mesenchymal origin that comprise 50 different histological subtypes. Many tyrosine kinases have been implicated as oncogenes in several sarcoma subtypes (summarized in Table 2 ), which has led to multiple clinical trials evaluating a range of targeted kinase therapies (readers are directed to a recent review [11] for an excellent overview of targeted therapies in sarcoma). These agents show limited efficacy as single agents in sarcoma trials because in many instances biomarkers that predict beneficial response to these agents have yet to be determined. Furthermore, in the majority of sarcoma subtypes, the identity of the key oncogenic drivers (including activated kinases) which drive disease progression remains elusive.
Pazopanib is a multi-target TKI which exhibits selectivity for receptor tyrosine kinases (RTKs), including VEGFR-1/2/3, PDGFR-α/β, FGFR-1/2, c-KIT as well as other kinases such as BRAF [41] [42] [43] . In addition to inhibiting VEGFR-mediated angiogenesis, direct inhibition of RTK signalling in tumour cells is also thought to contribute to its clinical efficacy [44] . The PALETTE phase III clinical trial showed that pazopanib increased progression-free survival from 1.6 to 4.6 months in patients with metastatic non-adipocytic soft tissue sarcoma (STS) after failure of standard chemotherapy [45] . As a consequence of this trial, pazopanib has been approved as a third-line treatment for patients with metastatic non-adipocytic STS.
Distinct STS subtypes show differential sensitivity to pazopanib, suggesting some subtype selectivity. Results from an EORTC phase II study reported higher progression-free survival at 12 weeks (PFS12) for leiomyosarcomas and synovial sarcomas versus a heterogeneous cohort of 'other' STS subtypes (44% and 49% versus 39%, respectively) [46] . Pazopanib has also demonstrated some activity in advanced desmoplastic small round cell tumours and solitary fibrous tumours (SFTs) [47, 48] . While patients with synovial sarcoma and leiomyosarcoma both display improved PFS, these two subtypes are driven by distinct genetic drivers [49, 50] which indicates that genomic information alone is insufficient to explain the apparent subtype sensitivity to pazopanib. In this respect, proteomic measurements of growth factor ligands and RTK activation may be particularly useful for identifying predictive biomarkers of TKI sensitivity. Indeed, proteomic interrogation of pro-angiogenic factors demonstrates that increased baseline plasma levels of hepatocyte growth factor and basic nerve growth factor correlated with worse PFS in pazopanib-treated patients [51] . It should also be noted that within the leiomyosarcoma and synovial sarcoma cohorts, there was a significant proportion of non-responders, highlighting our poor understanding of the mechanisms of drug sensitivity and the lack of reliable predictive biomarkers of response. The dearth of putative molecular predictive markers for response to TKI therapy suitable for incorporation into future clinical trial designs remains a significant barrier for the effective evaluation of targeted kinase therapies in sarcoma clinical trials.
A recent combined analysis of the PALETTE cohort and phase II EORTC trial data showed that 22% of sarcoma patients were both long-term responders (PFS ≥6 months) and longterm survivors (survived≥18 months) with 12 patients (3.5%) remaining on pazopanib for more than 2 years [52] . These durable responses are remarkable for TKI therapy where acquired resistance is almost universal. These exceptional responders warrant closer inspection to identify the biological basis by which tumours evade through acquired resistance mechanisms. It remains unresolved if this is a specific feature peculiar to Based on the phase II EORTC trial, pazopanib was deemed ineffective in liposarcoma; however, liposarcoma consists of at least three distinct biological subtypes: well-/dedifferentiated, myxoid/ round cell and pleomorphic. Ongoing clinical trials are evaluating the sensitivity of these liposarcoma subtypes to pazopanib and further work is required to rationally identify candidate druggable targets for this class of tumour [46] . Similarly for the majority of patients that eventually go on to develop acquired resistance to pazopanib [52] , it will be necessary to identify key bypass pathways and harness this information to develop new agents and combination strategies to circumvent pazopanib resistance.
phosphoproteomic applications in sarcoma biology: lessons from preclinical studies
The pazopanib experience illustrates the major challenges associated with clinical sarcoma research: (i) we do not fully understand the mechanisms of drug sensitivity and correspondingly do not know why some patients respond better than others. (ii) There are few reliable predictive biomarkers for patient stratification. (iii) There is an urgent need for alternative drug targets that are capable of overcoming primary and acquired drug resistance. Multiple preclinical studies in sarcoma suggest that phosphoproteomics may be a useful approach to address some of these issues [53] [54] [55] [56] [57] [58] [59] .
mechanisms of drug sensitivity
Previous studies using both MS-and affinity-based phosphoproteomics have shed light on possible mechanisms of sensitivity to TKIs in sarcoma patients. In a study to survey and define the functional tyrosine kinases driving sarcoma cell survival, Bai et al. [54] used MS-based phosphotyrosine enrichment to profile 10 sarcoma cell lines of 5 distinct subtypes. The authors found that multiple RTKs including EGFR, FGFR, IGF1R, c-KIT, c-MET and PDGFRA were simultaneously co-activated in the sarcoma cell lines examined. They subsequently carried out a drug screen with seven TKIs targeted against several of the RTKs identified and showed that this approach was capable in each case of identifying the specific driver RTK(s) that was responsible for cancer cell growth. The authors further demonstrated the potential clinical applications of this approach by analysing the phosphoproteome of human patient-derived murine xenograft models comprising liposarcoma, small round blue cell tumour and malignant peripheral nerve sheath tumour. Similar to the cell lines, multiple tyrosine kinases were found to be activated in the human tissue, indicating that this strategy may have clinical utility for the identification of mechanisms and biomarkers of TKI sensitivity in sarcoma patients.
Along the same lines, Rettew et al. [58] employed affinitybased RTK antibody arrays to screen two genetically distinct metastatic osteosarcoma cell lines for tyrosine kinase activation. They found that these cell lines activated up to nine RTKs simultaneously which were functionally validated using siRNA approaches and inhibitors for multiple measures of tumorigenicity, including cell motility, invasion, colony formation and cell growth. They showed that targeting 10 of the 12 RTKs by siRNA was capable of inhibiting the in vitro phenotype in at least one of the two cell lines used. The authors further demonstrated using immunohistochemistry that one of the identified RTKs (AXL) was activated in five of six osteosarcoma specimens examined, suggesting that this may be a new target for treating osteosarcoma patients. It should be noted that in both studies, the observation of a phosphorylated kinase is itself insufficient to predict its functional relevance in sarcoma cell growth or invasion. For instance, IGF1R was found to be phosphorylated in 9 of the 10 sarcoma cell lines examined by Bai et al., but only the Ewing sarcoma cell lines were sensitive to an IGF1R inhibitor. Similarly in the Rettew et al. study, none of the nine RTKs that were found to be phosphorylated in the two cell lines were validated in both metastatic osteosarcoma cellular models. This serves as a cautionary warning on the need to couple phosphoproteomic approaches with functional strategies such as RNAi, CRISPR or drug screens to distinguish the driver kinases from passenger events. The prevalence of RTK co-activation events in sarcoma cell lines and tissues may also explain why sarcomas are so challenging to treat using single-agent TKIs. The simultaneous activation of multiple RTKs enables cancer cells to maintain robust compensatory survival signalling in response to targeted inhibition of a specific RTK [60] . In order to effectively shut down oncogenic signalling and achieve durable tumour responses, combinations of TKIs that are capable of silencing multiple RTKs in individual patients may be required [61] .
predictive biomarkers for patient stratification Molecular profiling by phosphoproteomics has the potential to define predictive biomarkers to enable patient stratification for response to targeted therapy. In a study with the anti-angiogenesis TKI sunitinib, Stacchiotti et al. [59] employed RTK antibody arrays to examine the active RTKs in eight naïve SFT patient samples. They showed that in all SFTs examined, there was evidence of RTK co-activation where phosphorylation of PDGFRB, EGFR and IGF1R/IR were present at high levels. In addition, PDGFRA, RET and VEGFR1/2 were also found to be active in the tumours. In parallel, they conducted a clinical study in a group of 11 progressive advanced SFTs which were resistant to first-line chemotherapy who were treated with continuous dosing sunitinib. Among 10 patients who were evaluable for response at 6 months, 6 were stable according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria, while 4 progressed.
Two patients from this study were treated with sunitinib and underwent post-treatment surgery which provided a unique opportunity to compare the RTK alterations that accompanied TKI treatment. In one patient, the authors showed that a radiologically stable metastatic lesion displayed decreased phosphorylation levels of the sunitinib targets PDGFRB, PDGFRA, RET and VEGFR1 upon drug treatment, while a radiologically progressive lesion from another metastatic site showed an unchanged RTK activation profile in comparison with the pretreated sample, indicating that RTK phosphorylation may be a useful biomarker for TKI response. In the second patient where a radiologically progressive lesion was resected, the authors showed that PDGFRB and EGFR were more active post-treatment and other RTKs (M-CSFR and IGFR1R/IR) that were negative at presentation were now activated in the patient. They hypothesize that the loss of sunitinib efficacy over time could be the result of a shift in kinase dependency from PDGFRB to IGF1R/IR and that in such instances, the use of IGF1R-specific therapies may be warranted.
Phosphoproteomics have also been applied to enable patient stratification in rhabdomyosarcoma (RMS). Petricoin et al. [56] employed RPPA to analyse the levels of proteins associated with the AKT/mTOR pathway in micro-dissected tumour cells and found that activation of this pathway is negatively associated with RMS survival. Using specimens from the Children's Oncology Group intergroup RMS study with 12-year follow-up data, the authors showed that patients clustered into either a high or low AKT/mTOR signalling group with no statistical difference in the two clusters for clinically relevant prognostic factors commonly associated with RMS. They further identified significant association of specific phosphorylated components of the AKT/mTOR pathway (AKT, 4EBP1, eIF4G and p70S6) with disease-free and overall survival in two cohorts of 33 and 26 patients. Having determined that this pathway was enriched in patients with poor outcome, the authors functionally assessed if selective targeting of this pathway has any therapeutic value in two RMS xenograft models. Using the rapalog CCI-779, they showed that suppression of mTOR activity was capable of reducing RMS tumour growth in vivo. This study highlights the utility of phosphoproteomics in both identifying prognostic biomarkers and new therapeutic candidates for further development.
new target discovery
Dedifferentiated liposarcoma (DDLS) is a highly aggressive and metastatic disease which is resistant to chemotherapy. CDK4 is amplified (found within the 12q13-15 amplicon) in >90% of DDLS patients and is thought to be a driver kinase in this disease [62] . Palbociclib is a selective CDK4/6 inhibitor which has received Breakthrough designation from the Food and Drug Administration (FDA) due to its efficacy in breast malignancies [63] . A phase II clinical trial with palbociclib has shown limited activity in DDLS with low response rates, suggesting that alternative drivers may be present in this disease [64] . Miller et al. [55] sought to identify additional drivers by performing combinatorial screens of 14 targeted agents in a patient-derived DDLS cell line harbouring the 12q13-15 amplicon. Using all possible drugs as a single agent and pairwise combinations (a total of 105 perturbations), this combinatorial screen was coupled to phosphoproteomic measurements using RPPA technology. The authors identified a combination of a CDK4/6 inhibitor with an IGF1R inhibitor which had synergistic activity in multiple DDLS cell lines. They then developed network models based on the perturbation profiles (both phosphoproteomics and cell viability) and showed that repression of the AKT pathway and enhanced downregulation of mTOR signalling were involved in mediating the synergy in the combined CDK4 and IGF1R inhibition. Interestingly, dual blockade of CDK4 and IGF1R did not suppress the phosphorylation of ERK-MAP kinase pathway. Consistent with their hypothesis, combining CDK4 inhibition with AKT inhibitors was similarly synergistic in DDLS cell lines. This study indicates that hybrid experimental and computation approaches incorporating phosphoproteomics and drug screen data are capable of identifying new drug targets and combinations that could lead to improved efficacy.
Phosphoproteomic analysis can also be used as a tool for the discovery of new fusion kinases. Ren et al. [57] carried out phosphotyrosine MS-based profiling to identify the activated tyrosine kinases in a panel of 69 ovarian tumours, 2 of which were sarcoma cases. While information of the specific sarcoma subtype analysed was not provided, the authors found the ALK RTK to be aberrantly phosphorylated in one sarcoma patient. Upon closer examination, they determined that there were no ALK copy number gains in this patient but rather a novel inframe fusion of ALK with the fibronectin 1 (FN1) gene. This fusion (FN1-ALK) was constitutively active and promoted tumour formation in vivo. Promisingly, this FN1-ALK fusion was sensitive to inhibition by ALK TKIs Crizotiinib and TAE684 resulting in profound tumour shrinkage in vivo. Due to the small number of patients in this study and the lack of subtype identification, there remains a need to screen a larger cohort of patients in order to determine whether this novel fusion is a characteristic driver in sarcoma and a bona fide actionable target for disease. Nonetheless, it highlights the possibility that phosphoproteomics can provide novel information about fusion kinases in disease.
challenges and future perspectives
Although targeting multiple tyrosine kinases with different TKIs or monoclonal antibodies has yielded some success in the preclinical setting, the same approach may be difficult to translate directly into the clinic. For instance, the additional toxicity from a combination strategy would be a major limiting factor that is not often considered in pre-clinical studies [65, 66] . However, advances in the field of antibody engineering technologies and the development of multifunctional receptor-targeting antibodies may overcome these limitations [67] . Clinical trials with complimentary translational studies are thus required to further evaluate putative markers of response to therapy and to delineate mechanisms of resistance to specific drugs and combinations.
One major challenge in implementing phosphoproteomics as a component of such translational studies is in sample management and specimen integrity. This question was recently systematically evaluated by the National Cancer Institute Clinical Proteomics Tumour Analysis Consortium (NCI-CPTAC). A goal of CPTAC is to generate comprehensive proteomic and phosphoproteomic datasets of fully genomically characterized tumours for integration with genomic information generated by The Cancer Genome Atlas Consortium (TCGA) [68] . By providing an orthogonal but complementary molecular portrait of tumour specimens, this proteogenomic approach will conceptually enable a functional and more 'complete' understanding of disease biology [69] . Two recent studies from CPTAC assessed the temporal alterations in protein phosphorylation that accompany cold ischaemia (0-60 min) after debulking surgery in ovarian cancer patients [70, 71] . They showed that unlike global protein measurements which remain largely unaffected by cold ischaemia, tumour phosphorylation levels varied widely with temporal delay between resection and freezing. For instance, 4% of ∼9000 phosphoserine and phosphothreonine sites and 62% of 217 phosphotyrosine sites were perturbed when tumours were subjected to cold ischaemia. These alterations were (i) rapid, often occurring within 5 min of resection, (ii) unpredictable, where phosphorylation levels either increased and decreased in an unanticipated manner and (iii) patient-specific. In both studies, the authors were able to extract an ischaemia-regulated signature of common phosphoproteome alterations associated with cold ischaemia. These composed of proteins involved in stress response pathways, cell adhesion, migration and apoptosis. It remains to be determined if this signature can be readily translated to additional cancer types such as sarcoma. To prevent ischaemia-induced artefacts in the interpretation of phosphorylation data, the CPTAC studies highlight the importance of immediate freezing of tumour specimens after resection to preserve key signalling readouts for biomarker discovery and new target identification.
These challenges are further compounded by intratumour heterogeneity and clonal selection during treatment. Huge advances have been made in the treatment of gastrointestinal stromal tumour, which have been heralded as the paradigm for targeted therapy in solid tumours. However, clonal selection and heterogeneity are well documented in this particular subtype [72, 73] and again present obstacles for biomarker development even within genetically simpler tumour types. Furthermore, the complex interaction between the tumour stroma and tumour cells is difficult to capture in experimental models. The contribution of the tumour stroma to sarcoma progression and development of metastatic disease is not well understood. The effect of intratumoral spatial heterogeneity on cell signalling has also been assessed by CPTAC using MS-based phosphoproteomics [70] . The authors sampled spatially distinct regions from five colon cancer patients and found that while protein levels were consistent between different regions within the same tumour, phosphoproteomic levels varied dramatically. This finding reflects the spatial heterogeneity in cellular signalling and presents a major challenge in interpreting phosphoproteomic datasets from multiple biopsies. An exciting future prospect is to build on existing bioinformatic capabilities for the analysis of evolutionary genomic relationships between spatially separated tumour samples and deploy these tools to begin unravelling the complexities of cell signalling and intratumoural heterogeneity [74] . Additionally, new approaches for single-cell proteomic analysis using mass cytometry will complement population level measurements by delineating the individual contributions of tumour stromal subpopulations, including immune cells and cancer-associated fibroblasts to sarcoma progression, drug resistance and metastasis [75] .
In summary, although the number of systemic therapy options for advanced sarcoma patients is increasing, the outcome remains poor. Both the rarity of these tumours and the heterogeneity between histological subtypes present enormous challenges for biomarker and drug development. Clearly, international collaboration is required to overcome these obstacles and to develop an integrated approach to evaluating resistance mechanisms in sarcoma, coupling phosphoproteomic approaches with other established techniques in clinical trial design and accompanying translational studies. Continued efforts to achieve benchmarked phosphoproteomic gold standards across multiple sites and laboratories will be critical for routine implementation in sarcoma clinical trials. This is an exciting and evolving field which will hopefully lead to better outcomes for patients with sarcoma. 
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